Print Email Facebook Twitter Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas Title Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas Author Kleiburg, Fleur (University of Twente; Leiden University Medical Center) Heijmen, Linda (Leiden University Medical Center) Gelderblom, Hans (Leiden University Medical Center) Kielbasa, Szymon M. (Leiden University Medical Center) Bovée, Judith Vmg (Leiden University Medical Center) de Geus-Oei, L.F. (TU Delft RST/Radiation, Science and Technology; University of Twente; Leiden University Medical Center) Department RST/Radiation, Science and Technology Date 2023 Abstract Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may offer a new perspective. PSMA is a type II transmembrane glycoprotein which is present in all prostatic tissue and overexpressed in prostate cancer. Despite the name, PSMA is not prostate-specific. PSMA expression is also found in a multitude of non-prostatic diseases including a subgroup of sarcomas, mostly in its neovascular endothelial cells. On PET/CT imaging, multiple sarcomas have also shown intense PSMA-tracer accumulation. PSMA expression and PSMA-tracer uptake seem to be highest in patients with aggressive and advanced sarcomas, who are also in highest need of new therapeutic options. Although these results provide a good rationale for the future use of PSMA-targeted radioligand therapy in a selection of sarcoma patients, more research is needed to gain insight into optimal patient selection methods, PSMA-targeting antibodies and tracers, administered doses of radioligand therapy, and their efficacy and tolerability. In this review, mRNA expression of the FOLH1 gene which encodes PSMA, PSMA immunohistochemistry, PSMA-targeted imaging and PSMA-targeted therapy in sarcomas will be discussed. To reference this document use: http://resolver.tudelft.nl/uuid:d8860f47-83fc-4eda-91a0-9188f5605d90 DOI https://doi.org/10.1259/bjr.20220886 Source The British journal of radiology, 96 (1145), 20220886 Part of collection Institutional Repository Document type review Rights © 2023 Fleur Kleiburg, Linda Heijmen, Hans Gelderblom, Szymon M. Kielbasa, Judith Vmg Bovée, L.F. de Geus-Oei Files PDF bjr.20220886.pdf 2.32 MB Close viewer /islandora/object/uuid:d8860f47-83fc-4eda-91a0-9188f5605d90/datastream/OBJ/view